This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts See Merck (MRK) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Summit Incurs In-Line Q4 Loss, Inks Collaboration Deal With Pfizer
by Zacks Equity Research
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.
5 Stocks in the Dow ETF That Survived the Worst Week Since October
by Sweta Killa
Dow Jones witnesses its biggest weekly drop since October amid renewed concerns about economic growth. Let's look at the stocks that survived.
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis
by Zacks Equity Research
Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
by Kinjel Shah
EC approves MRK's Welireg for two indications. FDA grants priority review to SNY and REGN's Dupixent sBLA for bullous pemphigoid.
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
by Sundeep Ganoria
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
by Ekta Bagri
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
by Ahan Chakraborty
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
by Ekta Bagri
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
by Zacks Equity Research
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
by Zacks Equity Research
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' lackluster guidance for 2025 warrants caution. We recommend investors to wait and watch for the time being as generic competition for legacy drugs is a major headwind.
Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
When MRNA reports fourth-quarter earnings, investors will likely focus on pipeline updates.
Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings Update
by Kinjel Shah
PFE, LLY, NVO, LLY and AZN announce fourth-quarter earnings.
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
by Zacks Equity Research
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
by Zacks Equity Research
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has affected its 2025 sales forecast.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Pre-Markets Flat Ahead of JOLTS; Q4 Earnings for PFE, PYPL, PEP & More
by Mark Vickery
Pfizer (PFE) put up its most impressive quarterly numbers in recent memory today.
Merck (MRK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Merck (MRK) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 1.78% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
by Zacks Equity Research
Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.